Dr. Petros Grivas starts the discussion on how KEYNOTE-905 and KEYNOTE-B15 may translate into community bladder cancer care. The panel highlights practical barriers, including surgeon concerns about post-EV-pembrolizumab cystectomy, referral patterns, and familiarity with EV-based therapy. They also emphasize the need for stronger multidisciplinary coordination and broader medical oncology referral as perioperative systemic therapy expands treatment eligibility.
Contributors:
Dr. Petros Grivas is a medical oncologist and professor at the University of Washington and Fred Hutchinson Cancer Center in Seattle.
Dr. Bradley McGregor is a medical oncologist at Dana-Farber in Boston.
Dr. Ashish Kamat is a urologic oncologist at MD Anderson in Houston, Texas and president of The International Bladder Cancer Group.
Dr. Sia Daneshmand is a professor of urology and oncology at the University of Southern California, Norris Comprehensive Cancer Center.
Dr. Matthew Galsky is a medical oncologist at the Icahn School of Medicine at Mount Sinai.
Dr. Guru Sonpavde is a medical oncologist and the Phase 1 new drug development program Director at the AdventHealth Cancer Institute in Orlando, Florida.
